Mangalam Drugs and Organics share news and announcements
NSE: MANGALAMBSE: 532637Pharmaceuticals & BiotechnologySmall Cap
Last close ₹28.65down ₹0.92 (3.11%)BSE ₹28.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹29.57.
52-week range of traded prices to 23 Oct 2026
₹22.80Low, 29 Dec 2025₹71.99High, 23 Oct 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹45 Cr3,423rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 0.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- −30.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- −12.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 1.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 19,55176.4% delivered
Mangalam Drugs and Organics share news and announcements
527 announcements, routine notices left out, newest first. Page 5 of 11.
Apr 2022
15 Apr · Meeting
Mar 2022
Feb 2022
4 Feb · Board meeting
Jan 2022
Dec 2021
Nov 2021
12 Nov · Board meeting
Sep 2021
27 Sep · Management
27 Sep · Management
Aug 2021
12 Aug · Management
12 Aug · Board meeting
Jul 2021
12 Jul · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited with respect to announcement dated 05-Jul-2021, regarding Resignation of Statutory Auditor. On basis of above the Company is required to provide details w.r.t Annexure A of the SEBI Circular CIR/CFD/CMD1/114/2019 dated October18,2019. The response of the Company is awaited.6 Jul · Management
6 Jul · Board meeting
5 Jul · Board meeting
Jun 2021
9 Jun · Management
May 2021
20 May · Board meeting
Apr 2021
Mar 2021
21 Mar · Management
Feb 2021
Dec 2020
17 Dec · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited with respect to announcement dated 07-Dec-2020, regarding "Resignation of Mr Prashant J Pandit as Non- Executive Independent Director of the company w.e.f. December 02, 2020."On basis of above the Company is required to clarify following:1. No other material reasons other than providedThe response of the Company is awaited.